HLA-DR associations in black type I diabetics in Nigeria. Further support for models of inheritance

Diabetes ◽  
1986 ◽  
Vol 35 (5) ◽  
pp. 583-589 ◽  
Author(s):  
M. J. MacDonald ◽  
O. O. Famuyiwa ◽  
I. A. Nwabuebo ◽  
A. F. Bella ◽  
T. A. Junaid ◽  
...  
Keyword(s):  
Type I ◽  
Diabetes ◽  
1985 ◽  
Vol 34 (6) ◽  
pp. 565-567 ◽  
Author(s):  
E. Bhatia ◽  
N. K. Mehra ◽  
V. Taneja ◽  
M. C. Vaidya ◽  
M. M. Ahuja
Keyword(s):  
Type I ◽  
Hla Dr ◽  

2020 ◽  
Vol 8 (Suppl 2) ◽  
pp. A32.1-A32
Author(s):  
I Truxova ◽  
L Kasikova ◽  
C Salek ◽  
M Hensler ◽  
D Lysak ◽  
...  

In some settings, cancer cells responding to treatment undergo an immunogenic form of cell death that is associated with the abundant emission of danger signals in the form of damage-associated molecular patterns. Accumulating preclinical and clinical evidence indicates that danger signals play a crucial role in the (re-)activation of antitumor immune responses in vivo, thus having a major impact on patient prognosis. We have previously demonstrated that the presence of calreticulin on the surface of malignant blasts is a positive prognostic biomarker for patients with acute myeloid leukemia (AML). Calreticulin exposure not only correlated with enhanced T-cell-dependent antitumor immunity in this setting but also affected the number of circulating natural killer (NK) cells upon restoration of normal hematopoiesis. Here, we report that calreticulin exposure on malignant blasts is associated with enhanced NK cell cytotoxic and secretory functions, both in AML patients and in vivo in mice. The ability of calreticulin to stimulate NK-cells relies on CD11c+CD14high cells that, upon exposure to CRT, express higher levels of IL-15Rα, maturation markers (CD86 and HLA- DR) and CCR7. CRT exposure on malignant blasts also correlates with the upregulation of genes coding for type I interferon. This suggests that CD11c+CD14high cells have increased capacity to migrate to secondary lymphoid organs, where can efficiently deliver stimulatory signals (IL-15Rα/IL- 15) to NK cells. These findings delineate a multipronged, clinically relevant mechanism whereby surface-exposed calreticulin favors NK-cell activation in AML patients.Disclosure InformationI. Truxova: None. L. Kasikova: None. C. Salek: None. M. Hensler: None. D. Lysak: None. P. Holicek: None. P. Bilkova: None. M. Holubova: None. X. Chen: None. R. Mikyskova: None. M. Reinis: None. M. Kovar: None. B. Tomalova: None. J.P. Kline: None. L. Galluzzi: None. R. Spisek: None. J. Fucikova: None.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5439-5439
Author(s):  
Alexander Chan ◽  
Yanming Zhang ◽  
Sean M. Devlin ◽  
Natasha Lewis ◽  
Jeeyeon Baik ◽  
...  

Background Myelodysplastic syndrome (MDS) is a clonal, pre-leukemic stem cell disorder characterized by decreased blood counts due to ineffective hematopoiesis. Plasmacytoid dendritic cells (PDC) are stem cell derived, type I interferon producing dendritic cells, that are readily identifiable by flow cytometry (FC) using expression of CD123 and HLA-DR. PDCs have been shown to be decreased in acute myeloid leukemia (AML). Our study uses FC to evaluate PDC in MDS, their relationship to the Revised International Prognostic Scoring System (IPSS-R) for MDS, as well as their relationship to clinical outcomes. Methods We identified 197 patients with new MDS diagnoses and examined FC data of bone marrow aspirates (BMA) at first presentation to our institution for blast and PDC percentages. Patients who presented with an outside diagnosis of MDS greater than 1 year before presentation to our institution were excluded. MDS with excess blasts 1 and 2 (MDS-EB1/EB2) were designated as high grade, while MDS with isolated del5q (MDS-d5q), single lineage dysplasia (MDS-SLD), and multilineage dysplasia (MDS-MLD) were designated as low grade, with or without ring sideroblasts. 163 patients had sufficient data to calculate their IPSS-R risk categories. Sixteen patients with a history of solid tumor malignancies undergoing BMA for cytopenias were used as controls. The bone marrow of these control patients showed no evidence of morphologic dysplasia, they had normal karyotypes, and no pathogenic variants were detected on a 28 gene next generation sequencing based myeloid panel. We used CD34 and CD117 to quantify blasts, and CD123 and HLA-DR to quantify PDCs. Results The proportion of PDCs expressed as a percentage of total WBCs was significantly lower in higher risk MDS diagnoses (p <0.001) (Table 1A), as well as with worsening IPSS-R risk category (p <0.001) (Table 1B, Figure 1A). Sixteen percent of patients received disease modifying therapy (hypomethylating agents or lenalidomide) prior to presentation at our institution; PDC proportions in these patients were not significantly different from patients who presented untreated (p = 0.79). In the entire cohort, a lower proportion of PDC at the time of presentation was significantly associated with an increased risk of death (one-unit decrease in log PDC, HR 2.42, 95% CI 1.01-5.78, p = 0.046), but was not significantly associated with risk of progression to AML. Thirty-one patients progressed to AML, and these patients showed a significant decrease in the proportion of bone marrow PDCs at the time of progression to AML (p=0.002) (Table 1C, Figure 1B). Discussion This study demonstrates that PDC proportions decrease with MDS disease progression and are progressively lower as IPSS-R risk category increases. We also demonstrate that quantification of PDC in MDS can aid in predicting outcomes, although this may be due to a strong association with IPSS-R categories. FC is a useful and clinically feasible tool for quantitating PDCs in bone marrow aspirates, and this measurement is correlated with risk in MDS. Disclosures Arcila: Invivoscribe, Inc.: Consultancy, Honoraria. Roshal:Celgene: Other: Provision of Services; Auron Therapeutics: Equity Ownership, Other: Provision of services; Physicians' Education Resource: Other: Provision of services.


1996 ◽  
Vol 34 ◽  
pp. S133-S139 ◽  
Author(s):  
M SERRANORIOS ◽  
M GUTIERREZLOPEZ ◽  
F PEREZBRAVO ◽  
M MARTINEZ ◽  
J ANTONA ◽  
...  

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4915-4915
Author(s):  
Argiris S Symeonidis ◽  
George Theodorou ◽  
Constantina Repa ◽  
Theodore Marinakis ◽  
Panayiotis Tsaftaridis ◽  
...  

Abstract Patients with Gaucher disease exhibit substantial evidence of impairment of their immune system, namely, increased serum levels of proinflammatory cytokines and immunoglobulins, and increased incidence of B-cell malignancies, such as non-Hodgkin’s lymphoma, MGUS and multiple myeloma. We investigated peripheral blood T-lymphocyte subpopulations with dual color flow cytometry, as well as the direction of T-lymphocyte activation, by using intracytoplasmic immunostaining for IL-2, IL-4, IL-10 and IFN-gamma, on resting CD4+ and CD8+ T-lymphocytes and following activation with PMA- 1 with the presence of Brefeldin-A. Evaluations were performed on 16 patients with type I Gaucher disease and on 17 healthy controls. Patients had significantly decreased absolute lymphocyte count (1621±684 vs 2148±566/mm3, p=0.013), CD3+ (1197±478 vs 1508±431/mm3, p=0.045) and CD4+ T-lymphocytes (658±245 vs 945±253/mm3, p=0.021), but not CD8+ T-lymphocytes (491±331 vs 486±189/mm3, p: n.s.), resulting in a significant reduction of the CD4/CD8 ratio (1.59±0.68 vs 2.16±0.83, p=0.041). The populations of naive CD4+CD45RA+ and of memory CD4+CD45RO+ T-lymphocytes were also significantly decreased (218±128 vs 432±179/mm3, p=0.0005 and 484±185 vs 631±231/mm3, p=0.056 respectively), however, CD8+CD45RA+ and CD8+CD45RO+ subpopulations did nor differ significantly, when compared to controls. CD3−CD56+, but not CD3+CD56+ lymphocytes were also decreased (131±82 vs 199±97/mm3, p=0.037). Patients had higher percentages of CD8+ (29.2±9.7 vs 23.5±6.8%, p=0.042), CD8+CD45RA+ (22.1±6.2 vs 18.3±5.0%, p=0.046) and CD8+CD45RO+ T-lymphocytes (13.2±6.2 vs 9.6±3.7%, p=0.027), as well as of activated CD8+HLA-DR+ (0.93±0.68 vs 0.48±0.21%, p=0.008) and CD4+HLA-DR+ T-lymphocytes (1.77±0.93 vs 1.09±0.48%, p=0.008). Moreover, although both, the absolute number and the percentage of CD20+ B-lymphocytes were similar, patients exhibited significantly increased absolute number and percentage of CD5+CD20+ B-lymphocytes (1.63±0.55 vs 0.64±0.37% p=0.00002 and 29±20 vs 13±8/mm3, p=0.011, respectively). Finally, patients with Gaucher disease had significantly increased resting TH2-polarized CD4+T-lymphocytes (CD4+IL-10+: 0.41±0.29 vs 0.24±0.11%, p=0.045) and TH1-polarized CD8+ T-lymphocytes (CD8+IFNγ+: 0.15±0.07 vs 0.08±0.04%, p=0.005, CD8+IL10+: 0.22±0.08 vs 0.32±0.014, p=0.052, and IFNγ+/IL4+ ratio among the CD8+ population 2.54±2.1 vs 1.08±0.91, p=0.018). Following mitogenic activation a very significant impairment of obtaining the TH1 phenotype was observed (CD4+IL2+ lymphocytes 33.7±17.1 vs 65.4±6.1%, p&lt;0.00001). The above findings suggest that in patients with Gaucher disease there is a significant numerical impairment of T-helper lymphocytes and a shift towards TH-2 direction of lymphocyte activation. These findings may explain the rarity of autoimmune manifestations despite the chronic inflammatory reaction, as well as the increased incidence of lymphoid malignancies, which has been reported among patients suffering from this disease.


2000 ◽  
Vol 47 (1) ◽  
pp. 49-55 ◽  
Author(s):  
Kengo Nishimaki ◽  
Tomoyuki Kawamura ◽  
Hiroshi Inada ◽  
Kyoko Yagawa ◽  
Yoshisuke Nose ◽  
...  

2005 ◽  
Vol 5 (2) ◽  
pp. 72-79 ◽  
Author(s):  
E. Altobelli ◽  
A. Blasetti ◽  
R. Petrocelli ◽  
S. Tumini ◽  
R. Azzarone ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document